MedPath

Monitoring After Cardiac Arrest: Electroencephalogram and Cerebral Oximetry in Predicting Outcome

Completed
Conditions
EEG With Periodic Abnormalities
Hypoxic-Ischemic Encephalopathy
Cardiac Arrest
Registration Number
NCT06460480
Lead Sponsor
Haseki Training and Research Hospital
Brief Summary

Because of its high incidence, it is essential to determine the neurological prognosis after cardiac arrest. However, there is not much information to guide post-cardiac arrest care. Also, dynamic monitoring of the state of the brain can help provide information about the patient's prognosis other than previously described serum biomarkers. Therefore, the researchers will monitor postcardiac arrest patients in the intensive care unit for 48 hours by electroencephalogram and cerebral oximetry and collect blood samples for serum biomarkers: neuron-specific enolase (NSE), human neurogranin (NRGN) and human trigger receptor expressed on myeloid cells (TREM-2), which are associated with neuronal damage. And investigate the relation of these data to mortality.

Detailed Description

After cardiac resuscitation and intubation, the patient will be followed up with electroencephalogram-based monitoring and cerebral oximetry in the ICU for 48 hours. As standard, post-CPR patients will be sedated with midazolam (0.02- 0.1 mg/kg/s) and remifentanil (0.25- 0.5 mcq/kg/min) for 24 hours.

Brain function measurements will be recorded under sedation for the first 24 hours and without sedation for the second 24 hours. The values recorded were suppression ratio, suppression time, patient state index, oxyhemoglobin and deoxyhemoglobin, and regional oxygen saturation. After 24 hours, a 2 ml blood sample will be taken for biomarkers (NSE, NRGN, TREM-2). Patient survival will be followed up for seven days and 28 days.

The demographic data of the patients (age, gender, body mass index, ASA scores, comorbidities, history of previous operations), blood pressure, heart rate and SpO2, CPR duration, the reason for arrest(4H/4T), and inotropic-vasopressor support before and after arrest will be recorded; GCS, APACHE-2, and SOFA scores will be recorded when the patient is first admitted to the intensive care unit and at the time of cardiac arrest.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • experienced cardiac arrest
  • permanent spontaneous circulation is maintained for at least 48 hours after CPR
  • immediate intensive care follow-up after cardiac resuscitation
Exclusion Criteria
  • • Patients under 18 years of age

    • Presence of previously known neurological disease (cerebral palsy, neurodegenerative disease, encephalitis, etc.)
    • Immunosuppressive patients due to previously known hematological malignancy or solid tumor
    • Patients with a history of head trauma
    • Patients with cardiac arrest within 48 hours after spontaneous circulation is established
    • Patients sedated for more than 24 hours

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
late mortalityfrom the first day of intensive care admission after cardiac resuscitation until twenty eight days

the status of the patient as exitus or alive within twenty eight days post cardiac arrest

early mortalityfrom the first day of intensive care admission after cardiac resuscitation until seven days

the status of the patient as exitus or alive within seven days post cardiac arrest

Secondary Outcome Measures
NameTimeMethod
supression ratiofrom the first hour of intensive care admission until 48 hour

supression ratio is analyzed from the electroencephalogram monitorization as highest value during time frame

oxyhemoglobin deoxyhemoglobin ratiofrom the first hour of intensive care admission until 48 hour

oxyhemoglobin deoxyhemoglobin ratio is a calculated value on the cerebral oximetry monitorization and recorded as the highest deoxyhemoglobine and lowest oxyhemoglobine values

serum biomarkerspost-cardiac arrest 24th hour

serum biomarkers as NSE, NRGN, TREM2 will be studied in the blood sample at 24 th hour of post cardiac arrest

Trial Locations

Locations (1)

Haseki Training and Research Hospital

🇹🇷

Istanbul, Sultangazi, Turkey

© Copyright 2025. All Rights Reserved by MedPath